HeartSciences (HSCS) Projected to Post Earnings on Thursday

HeartSciences (NASDAQ:HSCS) is projected to issue its results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

HeartSciences (NASDAQ:HSCS) last announced its quarterly earnings data on Monday, December 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.05. The company had revenue of $2.42 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect HeartSciences to post $-10 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

HeartSciences Stock Performance

Shares of HSCS opened at $2.62 on Thursday. HeartSciences has a twelve month low of $2.01 and a twelve month high of $6.47. The firm has a market capitalization of $8.33 million, a P/E ratio of -0.38 and a beta of 2.53. The firm’s 50-day moving average is $3.07 and its two-hundred day moving average is $3.11.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new position in HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent quarter. Institutional investors own 17.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HSCS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. Ascendiant Capital Markets lifted their price target on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.20.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.